Movasin
Movasin: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Drug interactions
- 11. Analogs
- 12. Terms and conditions of storage
- 13. Terms of dispensing from pharmacies
- 14. Reviews
- 15. Price in pharmacies
Latin name: Movasin
ATX code: M01AC06
Active ingredient: Meloxicam (Meloxicam)
Producer: JSC Sintez (Russia)
Description and photo update: 2019-12-08
Prices in pharmacies: from 57 rubles.
Buy
Movasin is a selective COX-2 inhibitor, non-steroidal anti-inflammatory drug (NSAID).
Release form and composition
Dosage forms of Movasin:
- Tablets: flat-cylindrical, round, light yellow in color (a slight marbling of color may be noted on the surface), with a chamfer (in blisters of 10 pcs., 1 or 2 packages in a cardboard box);
- Solution for intramuscular (i / m) administration: transparent (may be slightly opalescent), yellow with a greenish tinge (in 1.5 ml glass ampoules, 3 or 5 ampoules in blisters, 1 package in a cardboard box).
The active ingredient is meloxicam:
- 1 tablet - 7.5 or 15 mg;
- 1 ampoule of solution - 15 mg.
Tablets excipients: povidone 12 600, crospovidone (Kollidon CL-M), microcrystalline cellulose, potato starch, lactose monohydrate, magnesium stearate, talc.
Additional substances in the solution: sodium chloride, meglumine, glycine, glycofurfural, sodium chloride, sodium hydroxide, poloxamer 188, water for injection.
Pharmacological properties
Pharmacodynamics
Movasin (active ingredient - meloxicam) is a non-steroidal anti-inflammatory drug, characterized by anti-inflammatory, antipyretic and analgesic effects. The substance inhibits the synthesis of prostaglandins due to the selective inhibition of the enzymatic activity of cyclooxygenase-2 (COX-2), which takes part in the biosynthesis of prostaglandins in the focus of inflammation. With prolonged therapy, use in high doses and individual characteristics of the organism, a decrease in selectivity towards COX-2 is observed.
Meloxicam inhibits the production of prostaglandins in the focus of inflammation to a greater extent than in the kidneys or gastric mucosa, which is due to the relatively selective inhibition of COX-2 activity. Less commonly, the substance becomes the cause of the development of erosive and ulcerative diseases of the gastrointestinal tract. To a lesser extent, meloxicam affects cyclooxygenase-1 (COX-1), which is partially responsible for the synthesis of prostaglandins, which are involved in the regulation of blood flow in the kidneys and protect the gastrointestinal mucosa.
Pharmacokinetics
When taken orally, meloxicam is well absorbed from the gastrointestinal tract, and its absolute bioavailability is 89%. The degree and rate of absorption do not change with simultaneous food intake. With oral administration of Movasin in doses of 7.5 and 15 mg, its concentrations are directly proportional to doses. Equilibrium concentrations of the active ingredient are reached within 3-5 days. With prolonged use of the drug (more than 12 months), the level of meloxicam is similar to that observed after the first achievement of stable equilibrium concentrations.
Meloxicam binds to plasma proteins by more than 99%. The differences between the maximum and basal concentrations of the drug after taking it once a day are insignificant: when using a dose of 7.5 mg, the range of values is 0.4–1 μg / ml, and when using a dose of 15 mg, 0.8–2 μg / ml (the values of the minimum and maximum concentrations are indicated, respectively).
Meloxicam overcomes histohematological barriers, and its content in the synovial fluid is equal to 50% of the maximum concentration of the substance in the blood plasma. The compound is almost completely metabolized in the liver, forming four pharmacologically inactive derivatives. The main metabolite is 5'-carboxymeloxicam (60% of the dose taken), formed by oxidation of the intermediate metabolite 5'-hydroxymethylmeloxicam, which is also excreted, but in a smaller amount (about 9% of the dose taken).
In vitro studies prove that the isoenzyme CYP2C9 plays an active role in this metabolic process, with the additional participation of the auxiliary isoenzyme CYP3A4. Two other metabolites (their number is 16% and 4% of the taken dose of Movasin, respectively) are formed using peroxidase, the activity of which changes in each individual case.
Meloxicam is approximately equally excreted in urine and faeces, mainly in the form of metabolites. Less than 5% of the daily dose is excreted unchanged through the intestines; only traces of unchanged meloxicam can be found in the urine. The half-life of the substance is 15–20 hours. Plasma clearance is approximately 8 ml / min. In elderly patients, Movasin's clearance decreases. The volume of distribution is small and is about 11 liters. Renal or hepatic failure of moderate severity does not significantly affect the pharmacokinetic properties of meloxicam.
With intramuscular administration, bioavailability reaches 100%, and after administration of a solution at a dose of 5 mg, the maximum concentration is 1.62 μg / ml and is detected in the blood already 60 minutes after the drug enters the body.
Indications for use
Movasin is a drug for the symptomatic treatment of the following diseases of the musculoskeletal system:
- Rheumatoid arthritis;
- Osteoarthritis;
- Bechterew's disease (ankylosing spondylitis).
Contraindications
- Children under 12 years old - for tablets, up to 18 years old - for solution for intramuscular injection;
- Pregnancy and lactation period;
- Chronic renal failure in patients not undergoing dialysis (creatinine clearance less than 30 ml / minute), progressive kidney disease (including confirmed hyperkalemia);
- Severe liver failure, active liver disease;
- Complete or incomplete combination of bronchial asthma, recurrent polyposis of the nasal mucosa / paranasal sinuses and intolerance to nonsteroidal anti-inflammatory drugs, including acetylsalicylic acid (including a history);
- Cerebrovascular or other bleeding;
- Inflammatory bowel disease (such as ulcerative colitis or Crohn's disease);
- Active gastrointestinal bleeding, erosive and ulcerative lesions of the gastric mucosa or 12 duodenal ulcer;
- Decompensated heart failure;
- Condition after coronary artery bypass grafting;
- Lactase deficiency, galactose intolerance, glucose-galactose malabsorption;
- Hypersensitivity to drug components.
According to the instructions, Movasin should be used with caution in the following cases:
- Concomitant therapy with one of the following drugs: selective serotonin reuptake inhibitors (including sertraline, fluoxetine, citalopram, paroxetine), antiplatelet agents (including acetylsalicylic acid and clopidogrel), anticoagulants, oral glucocorticosteroids;
- Long-term use of NSAIDs;
- Elderly age;
- Smoking;
- Frequent alcohol consumption;
- Severe somatic diseases;
- Dyslipidemia or hyperlipidemia;
- The presence of Helicobacter pylori infection;
- Anamnestic data on ulcerative lesions of the gastrointestinal tract;
- Creatinine clearance 30-60 ml / minute;
- Heart failure in compensation stage;
- Cerebrovascular disease;
- Peripheral artery disease;
- Cardiac ischemia;
- Diabetes.
Instructions for the use of Movasin: method and dosage
Pills
Movasin tablets should be taken orally 1 time per day with meals.
Recommended doses:
- Ankylosing spondylitis: 15 mg per day;
- Rheumatoid arthritis: 15 mg per day, if necessary, the dose is reduced to 7.5 mg;
- Osteoarthritis: 7.5 mg per day, in case of insufficient therapeutic effect, the dose is increased to 15 mg.
The highest permitted daily dose is 15 mg, for patients with renal failure on hemodialysis and for patients with an increased risk of developing adverse effects - 7.5 mg.
Solution for intramuscular injection
Movasin in the form of a solution for intramuscular injection is injected deep into the muscle once a day.
Depending on the severity of the inflammatory process and the severity of the pain syndrome, the dose is 7.5 or 15 mg.
The highest permitted daily dose is 15 mg, for patients with mild and moderate functional impairment of the kidneys (creatinine clearance of more than 30 ml / minute), for patients with end-stage renal failure on hemodialysis and for persons with an increased risk of developing undesirable effects, 7.5 mg.
The IM drug is used only for the first 2-3 days. If it is necessary to continue treatment, the patient is prescribed Movasin tablets.
When combining different dosage forms of Movasin, it should be borne in mind that the total daily dose of meloxicam should not exceed 15 mg.
Side effects
- From the digestive system: often (more than 1% of cases) - dyspeptic disorders (nausea, abdominal pain, flatulence, constipation / diarrhea, vomiting); infrequently (0.1-1% of cases) - stomatitis, belching, hyperbilirubinemia, esophagitis, transient increase in the activity of hepatic transaminases, bleeding from the gastrointestinal tract (including latent), ulcer in the gastroduodenal zone; rarely (less than 0.1% of cases) - perforation of the gastrointestinal tract, colitis, gastritis, hepatitis;
- From the urinary system: infrequently - increased serum urea and / or hypercreatininemia; rarely - acute renal failure; isolated cases (the connection with the use of meloxicam has not been proven) - hematuria, albuminuria, interstitial nephritis;
- From the side of the cardiovascular system: often - peripheral edema; infrequently - rush of blood to the skin of the face, increased blood pressure, palpitations;
- On the part of the hematopoietic organs: often - a decrease in the concentration of hemoglobin in the blood; infrequently - a change in the blood count, including thrombocytopenia, leukopenia;
- From the side of the skin: often - itching and rash on the skin; infrequently - urticaria; rarely - erythema multiforme, toxic epidermal necrolysis, bullous eruptions, photosensitization;
- From the senses: rarely - conjunctivitis, visual impairment (including blurred visual perception);
- From the respiratory system: rarely - bronchospasm;
- From the nervous system: often - headache; infrequently - tinnitus, drowsiness, vertigo; rarely - confusion, unstable mood, disorientation;
- Local reactions with intramuscular injection: often - swelling; rarely - soreness at the injection site;
- Allergic reactions: rarely - angioedema, anaphylactic / anaphylactoid reactions.
Overdose
Symptoms of an overdose of Movasin are pain in the epigastric region, nausea, vomiting, gastrointestinal bleeding, liver failure, acute renal failure, asystole, respiratory arrest, impaired consciousness.
There is no specific antidote. When taking the drug in high doses, it is recommended to flush the stomach and take activated charcoal (during the first hour), as well as prescribe symptomatic therapy. Hemodialysis, urine alkalization, forced diuresis are not very effective due to the high degree of binding of meloxicam to blood proteins.
special instructions
Movasin should be used with caution in the elderly, patients with liver cirrhosis, chronic heart failure with symptoms of circulatory failure and patients with hypovolemia resulting from surgery. During treatment, it is necessary to monitor the indicators of renal function.
To reduce the risk of developing side effects from the digestive system, it is recommended to use the lowest effective dose for the shortest possible course.
Intravenous administration of Movasin solution is prohibited!
Patients receiving meloxicam at the same time as diuretics should take a sufficient amount of fluids.
Like all NSAIDs, Movasin can mask the symptoms of infectious diseases.
The drug can cause drowsiness, headache and dizziness, therefore, during the period of therapy, it is worth refusing to drive a car and engage in activities with potentially dangerous consequences (which require increased attention).
Application during pregnancy and lactation
The period of pregnancy and breastfeeding is a contraindication to the appointment of Movasin. Its use can affect fertility, therefore, drug treatment is not recommended for women seeking to become pregnant.
Drug interactions
- Other NSAIDs, including acetylsalicylic acid: the risk of erosive and ulcerative lesions and bleeding of the gastrointestinal tract increases;
- Selective serotonin reuptake inhibitors: increases the likelihood of bleeding from the gastrointestinal tract;
- Antihypertensive drugs: their effectiveness decreases;
- Lithium preparations: accumulation of lithium develops, its toxic effect increases (if it is necessary to use such a combination, the level of lithium in the blood should be monitored);
- Methotrexate: the risk of developing leukopenia and anemia, toxic effects on hematopoiesis increases (a complete blood count should be done periodically);
- Diuretics, cyclosporine: the risk of developing renal failure increases;
- Cholestyramine: increased excretion of meloxicam through the gastrointestinal tract;
- Anticoagulants (including warfarin, heparin, ticlopidine), thrombolytic drugs (including streptokinase, fibrinolysin): the risk of bleeding increases (when using such a combination, the blood clotting system should be monitored);
- Intrauterine contraceptives: their effectiveness decreases.
Analogs
Movasin's analogs are: Ksefokam, Piroxicam, Texamen, Larfix, Oxyten, Lorakam, Brexin, Tenoctil, Amelotex, Meloxicam, Meloxicam-Teva, Artrozan, Melbek, Meloflam, Movalis, Movix, Liberum.
Terms and conditions of storage
Store in a dry and dark place, out of the reach of children, at a temperature: tablets - no more than 25 ºС, solution for intramuscular administration - no more than 30 ºС.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Movasin
According to reviews, Movasin is a highly effective pain reliever. In many cases, it helps to relieve pain attacks associated with diseases of the musculoskeletal system, and does not have such pronounced side effects as non-steroidal anti-inflammatory drugs of previous generations.
However, experts recommend not to abuse Movasin and use it as little as possible. This is due to the fact that frequent use or intramuscular administration of meloxicam can provoke serious complications in the gastrointestinal tract (bleeding, peptic ulcer disease, erosion, etc.).
The price of Movasin in pharmacies
The price of Movasin in tablets with a dosage of 7.5 mg is approximately 46–79 rubles, and with a dosage of 15 mg - 85–117 rubles (20 pcs per pack). A solution for intramuscular administration with a dosage of 15 mg will cost about 74–96 rubles (for a package consisting of 3 ampoules).
Movasin: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Movasin 7.5 mg tablets 20 pcs. RUB 57 Buy |
|
Movasin 10 mg / ml solution for intramuscular administration 1.5 ml 3 pcs. RUB 67 Buy |
|
Movasin tablets 7.5mg 20 pcs. RUB 68 Buy |
|
Movasin 15 mg tablets 20 pcs. 79 RUB Buy |
|
Movasin tablets 15mg 20 pcs. 106 RUB Buy |
|
Movasin 10 mg / ml solution for intramuscular administration 1.5 ml 5 pcs. 110 RUB Buy |
|
Movasin solution for intramuscular injection 10mg / ml 1.5ml 3 pcs. RUB 128 Buy |
|
Movasin solution for intramuscular injection 10mg / ml 1.5ml 5 pcs. RUB 200 Buy |
| See all offers from pharmacies |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
